Vyloy
Payments companies reported to CMS as associated with Vyloy. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vyloy, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vyloy
These are the largest totals companies reported as associated with Vyloy. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ronan Kelly | Dallas, TX | Medical Oncology | $115,905.53 |
| Maen Abdelrahim | Houston, TX | Medical Oncology | $97,159.31 |
| Farshid Dayyani | Orange, CA | Medical Oncology | $93,337.86 |
| Amit Mahipal | Rochester, MN | Medical Oncology | $61,769.43 |
| Syma Iqbal | Los Angeles, CA | Medical Oncology | $52,860.03 |
| Shirley Shiller | Nashville, TN | Anatomic Pathology & Clinical Pathology | $52,847.60 |
| Ben George | Rochester, MN | Medical Oncology | $43,515.96 |
| Teri Longacre | Stanford, CA | Anatomic Pathology & Clinical Pathology | $38,758.50 |
| Putao Cen | Houston, TX | Medical Oncology | $37,813.60 |
| Arlene Ortega | San Diego, CA | Nurse Practitioner | $37,716.40 |
Prescribed Vyloy?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.